Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells

Journal of Orthopaedic Research

Volumn 29, Issue 6, 2011, Pages 846-852

  Zhou, Rongping ^a,b   Zhang, Zhongmin ^a,b   Zhao, Li ^a   Jia, Chunhong ^a   Xu, Song ^a,b   Mai, Qiguang ^a,b   Lu, Ming ^a,b   Huang, Mingjun ^a,b   Wang, Liang ^a,b   Wang, Xiaokai ^a,b   Jin, Dadi ^a,b   Bai, Xiaochun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; mTOR; oleanolic acid; osteosarcoma; proliferation

Indexed keywords

CASPASE 3; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLEANOLIC ACID; PROTEIN KINASE B; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; HUMANS; OLEANOLIC ACID; OSTEOSARCOMA; PROTEINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 79955483906     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21311     Document Type: Article

References (35)

1. Biermann JS, Adkins D, Benjamin R, et al. 2007. Bone cancer. J Natl Compr Canc Netw 5: 420-437.
2. Demetri GD, Baker LH, Benjamin RS, et al. 2007. Soft tissue sarcoma. J Natl Compr Canc Netw 5: 364-399.
3. Marina N, Gebhardt M, Teot L, Gorlick R,. 2004. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441. (Pubitemid 39014554)
4. Meyers PA, Gorlick R,. 1997. Osteosarcoma. Pediatr Clin North Am 44: 973-989. (Pubitemid 27368674)
5. Ebeid W, Amin S, Abdelmegid A,. 2005. Limb salvage management of pathologic fractures of primary malignant bone tumors. Cancer Control 12: 57-61.
6. Longhi A, Errani C, DePaolis M, et al. 2006. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436. (Pubitemid 44309249)
7. Hua Y, Zhang Z, Li J, et al. 2009. Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo. Invest New Drugs [Epub ahead of print. DOI: 10.1007/s 10637-009-9354-1].
8. Sporn MB, Suh N,. 2000. Chemoprevention of cancer. Carcinogenesis 21: 525-530. (Pubitemid 30137938)
9. Zhang P, Li H, Chen D, et al. 2007. Oleanolic acid induces apoptosis in human leukemia cells through caspase activation and poly(ADP-ribose) polymerase cleavage. Acta Biochim Biophys Sin (Shanghai) 39: 803-809. (Pubitemid 47631044)
10. Ryu SY, Oak MH, Yoon SK, et al. 2000. Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med 66: 358-360. (Pubitemid 30346302)
11. Liby KT, Yore MM, Sporn MB,. 2007. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369. (Pubitemid 46652485)
12. Konopleva M, Tsao T, Estrov Z, et al. 2004. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64: 7927-7935. (Pubitemid 39446926)
13. Dorrah D, Xiaohua G, Hao J, et al. 2009. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate 69: 851-860.
14. Wullschleger S, Loewith R, Hall MN,. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484. (Pubitemid 43199434)
15. Loewith R, Jacinto E, Wullschleger S, et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468. (Pubitemid 35284167)
16. Bai X, Ma D, Liu A, et al. 2007. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980. (Pubitemid 350098994)
17. Easton JB, Houghton PJ,. 2006. mTOR and cancer therapy. Oncogene 16: 6436-6446. (Pubitemid 44582287)
18. Sparks CA, Guertin DA,. 2010. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744.
19. Faivre S, Kroemer G, Raymond E,. 2006. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688. (Pubitemid 44151605)
20. Zhou Q, Deng Z, Zhu Y, et al. 2009. mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol [Epub ahead of print. DOI: 10.1007/s 12032-009-9365-Y].
21. Gordon IK, Ye F, Kent MS,. 2008. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 69: 1079-1084.
22. Geryk-Hall M, Hughes DP,. 2009. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 11: 446-453.
23. Guertin DA, Sabatini DM,. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. (Pubitemid 47001784)
24. Nishioka C, Ikezoe T, Yang J, et al. 2008. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22: 2159-2168.
25. Li J, Guo WJ, Yang QY,. 2002. Effects of ursolic acid and oleanolic acid on human colon carcinoma cell line HCT15. World J Gastroenterol 8: 493-495. (Pubitemid 34692749)
26. Sarbassov DD, Guertin DA, Ali SM, et al. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
27. Roulin D, Cerantola Y, Dormond-Meuwly A,. 2010. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 9: 57-60.
28. Chintharlapalli S, Papineni S, Konopleva M, et al. 2005. 2-Cyano-3,12- dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 68: 119-128. (Pubitemid 41002950)
29. Shishodia S, Sethi G, Konopleva M, et al. 2006. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 12: 1828-1838.
30. Konopleva M, Contractor R, Kurinna SM, et al. 2005. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19: 1350-1354. (Pubitemid 41136327)
31. Deeb D, Gao X, Dulchavsky SA, Gautam SC,. 2007. CDDO-Me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res 27: 3035-3044. (Pubitemid 47607524)
32. Ahmad R, Raina D, Meyer C, Kufe D,. 2008. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)âsignal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 68: 2920-2926. (Pubitemid 351556292)
33. Suh N, Roberts AB, Birkey Reffey S, et al. 2003. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63: 1371-1376. (Pubitemid 36348719)
34. Konopleva M, Zhang W, Shi YX, McQueen T, et al. 2006. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 5: 317-328.
35. Gao X, Deeb D, Jiang H, et al. 2007. Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NFkappaB and Notch1 signaling. J Neurooncol 84: 147-157. (Pubitemid 47202123)